NicOx looks ahead to NDA filing for anti-inflammatory agent

NicOx SA said it is moving ahead with plans to file a new drug application (NDA) with the US Food and Drug Administration for its anti-inflammatory agent, naproxcinod, which has completed Phase 3 trials in patients with osteoarthritis.